ライフサイエンスコーパス: activator protein-1

1 ctivator, but not activator Rap1p (repressor-activator protein 1).

2 CCL2-regulating transcription factor, AP-1 (activator protein-1).

3 eta V1, likely via nuclear factor kappaB and activator protein 1.

4 ays, and this induction of activity requires activator protein 1.

5 hat COX-2 gene transcription is regulated by activator protein-1.

6 -responsive transcription factors, including activator protein-1.

7 of the transcription factors NF- kappa B and activator protein-1.

8 ppaB (NF-kappaB) and c-Jun N-terminal kinase/activator protein-1.

9 ed to involve transcription factors, Sp1 and activator protein-1.

10 loproteinases driving the induction of c-Jun/activator protein-1.

11 ytokine secretion, nuclear factor kappaB and activator protein 1 activation, mitogen-activated protei

12 ediated mitogen-activated protein kinase and activator protein-1 activation, and epithelial to mesenc

13 ady-state level of c-Jun, thereby inhibiting activator protein-1 activity and cell transformation cau

14 phosphorylation is critical for controlling activator protein-1 activity, which is a major driver in

15 ed for nuclear factor kappaB (NF-kappaB) and activator protein-1 activity.

16 AP-1 (activator protein 1) activity is strongly induced in res

17 V6 expression is through EGR1-mediated AP-1 (activator protein-1) activity and that the EGR1- and AP-

18 by multiple transcription factors, including activator protein 1 and cAMP response element-binding pr

19 es activities of other DNA-bound regulators, activator protein 1 and nuclear factor kappaB, utilizing

20 and miR-466l regulated transcription factors activator protein 1 and nuclear factor kappaB1 in miRNA

21 rosis factor alpha expression, and increased activator protein 1 and nuclear factor-kappaB transcript

22 s: extracellular signal-regulated kinase 1/2-activator protein 1 and signal transducer and activator

23 d a trend for increased NF-AT, but decreased activator protein 1 and similar NF-kappaB, activity in C

24 ndently attenuated TPA-induced activation of activator protein-1 and c-fos, whereas daidzein did not

25 dose, many of which are under the control of activator protein-1 and ERK signaling.

26 he +1123/+1134 region harbored non-consensus activator protein-1 and Ets1 binding sites bound with c-

27 Furthermore, the activation of activator protein-1 and interleukin-2 induced by CD3 was

28 otein-1 (GRIP1), GR tethers to the DNA-bound activator protein-1 and NF-kappaB and represses transcri

29 The activation of activator protein-1 and nuclear factor-kappaB induced by

30 The activation of activator protein-1 and nuclear factor-kappaB induced by

31 9 in vitro, which required activation of the activator protein-1 and nuclear factor-kappaB signaling

32 ivation was specific, inasmuch as binding of activator protein-1 and octameric transcription factor 1

33 tant synapses, c-Jun N-terminal kinase (JNK)/activator protein-1 and TGF-beta signaling were overacti

34 ogic events through the transcription factor activator protein-1 and transcription-independent contro

35 ly conserved JNK/AP-1 (Jun N-terminal kinase/activator protein 1) and BMP (Bone Morphogenetic Protein

36 g CD4(+) T cell activation: NF-kappaB, AP-1 (activator protein 1), and NFAT (nuclear factor of activa

37 h the JNK pathway, reduced the activation of activator protein 1, and decreased the expression of MMP

38 g of transcription factors nuclear factor-Y, activator protein 1, and specificity protein 1, respecti

39 s binding to transcription factors NFkappaB, Activator Protein-1, and CCAAT/enhancer-binding protein

40 55,212-2 acts via PPARalpha to activate JNK, activator protein-1, and positive regulatory domain IV t

41 presence of putative nuclear factor kappaB, activator protein-1, and STAT-1 response elements.

42 r; competition with the transcription factor activator protein 1; and reduced expression of histone d

43 We demonstrate that activator protein 1 (AP-1) 'pioneers' the senescence enh

44 The signal-dependent transcription factor activator protein 1 (AP-1) activates Notch4 transcriptio

45 ted T-cells (NFAT) c1, whereas NF-kappaB and activator protein 1 (AP-1) activation were not adversely

46 e effect of Tcl1 expression on NF-kappaB and activator protein 1 (AP-1) activity.

47 nase, and phospho-cJun, as well as decreased activator protein 1 (AP-1) activity.

48 cription factors nuclear factor (NF)-kappaB, activator protein 1 (AP-1) and CCAAT/enhancer binding pr

49 We further linked JNK to RUNX1 through Activator Protein 1 (AP-1) and investigated the JNK-AP-1

50 evaluated by luciferase reporter assays for activator protein 1 (AP-1) and NF-kappaB.

51 Activation of activator protein 1 (AP-1) and nuclear factor kappaB (NF

52 marked increase in UV-induced activation of activator protein 1 (AP-1) and nuclear factor kappaB (NF

53 ed HSPC specification by activating a unique activator protein 1 (AP-1) and runx1 transcription progr

54 nhancer of activated B cells (NF-kappaB) and activator protein 1 (AP-1) are transcription factors act

55 Activator protein 1 (AP-1) binding and transcriptional a

56 Radiation-induced AC gene transactivation by activator protein 1 (AP-1) binding on the proximal promo

57 In contrast, methylation of CpGs in the activator protein 1 (AP-1) binding sites was low but was

58 c-Jun transcription factors, members of the activator protein 1 (AP-1) complex, form heterodimers an

59 K), phosphorylates c-Jun, a component of the activator protein 1 (AP-1) early response transcription

60 2-related factor 2 (Nrf2) and members of the activator protein 1 (AP-1) family of proteins.

61 restrict expression of JunB, a member of the activator protein 1 (AP-1) family of transcription facto

62 f interferon regulatory factor 4 (IRF4) with activator protein 1 (AP-1) family proteins and STAT3 in

63 ctor 7) are highly homologous members of the activator protein 1 (AP-1) family.

64 Activator protein 1 (AP-1) is a pivotal transcription fa

65 T: Activator protein 1 (AP-1) is a transcription factor tha

66 The transcription factor activator protein 1 (AP-1) is formed through the dimeriz

67 The transcription factor activator protein 1 (AP-1) is involved in cellular proli

68 d to measure the effect of Smad3, MAPKs, and activator protein 1 (AP-1) on TGFbeta-mediated CCN3 prom

69 measure the effects of Smads 2, 3, and 7 and activator protein 1 (AP-1) on TGFbeta-mediated CTGF prom

70 factors nuclear factor kappaB (NFkappaB) and activator protein 1 (AP-1) regulate key proinflammatory

71 a cyclic AMP response element (CRE) and two activator protein 1 (AP-1) response elements in the muri

72 oter by H. pylori involved occupation of the activator protein 1 (AP-1) sites at -72 and -181 and, su

73 FAT), nuclear factor kappaB (NF-kappaB), and activator protein 1 (AP-1) to induce type 2 cytokines.

74 ctivation of specific signaling proteins and activator protein 1 (AP-1) to regulate cell cycle regres

75 Hypoxia-inducible factor 1 (HIF-1) and activator protein 1 (AP-1) transcription complexes were

76 show that in Drosophila, quenching of basal activator protein 1 (AP-1) transcription factor activity

77 The actin-binding protein Ezrin and the activator protein 1 (AP-1) transcription factor are impl

78 Activation of the activator protein 1 (AP-1) transcription factor as well

79 ding enhancer element that contains multiple activator protein 1 (AP-1) transcription factor binding

80 d, and normal cellular FOS forms part of the activator protein 1 (AP-1) transcription factor complex,

81 JUN proto-oncogene, which forms part of the activator protein 1 (AP-1) transcription factor complex.

82 The Activator Protein 1 (AP-1) transcription factor subunit

83 K activation was required for the binding of activator protein 1 (AP-1) transcription factor to the M

84 Activator protein 1 (AP-1) transcription factors become

85 Following shear-flow exposure, six activator protein 1 (AP-1) transcripts (ATF4,JUNB,JUN,FO

86 Activation of NF-kappaB and activator protein 1 (AP-1) was evaluated by electrophore

87 The expression of the activator protein 1 (AP-1) was increased in lung tissues

88 Additionally, activator protein 1 (AP-1) was shown to be essential in

89 he nuclear factor kappaB (NF-kappaB) and the activator protein 1 (AP-1) with a corresponding depletio

90 ription factors, nuclear factor (NF)-kappaB, activator protein 1 (AP-1), and interferon regulatory fa

91 mponent of the transcription factor complex, activator protein 1 (AP-1), and promoted SIRT1 associati

92 -activated protein (MAP) kinase signaling to activator protein 1 (AP-1), and thus contribute to resis

93 We found that activator protein 1 (AP-1), Ets related gene (Erg) and G

94 ellular signal-regulated kinase 1/2 (Erk1/2)-activator protein 1 (AP-1), known collectively as the Ra

95 downstream target gene c-fos, a component of activator protein 1 (AP-1), that directly regulates epit

96 inal kinase (JNK), results in stimulation of activator protein 1 (AP-1), which promotes gene transcri

97 promoter and exhibit a strong enrichment for activator protein 1 (AP-1)-binding events, suggesting th

98 nt in mammals, shares functionally essential activator protein 1 (AP-1)-binding motifs, and responds

99 gene regulation by the transcription factor activator protein 1 (AP-1).

100 Activator protein 1 (AP-1, also known as JUN) transcript

101 bital-responsive enhancer module (PREM), and activator protein 1 (AP-1-) -driven pathways.

102 proximal cAMP-response element (-45/-38) or activator protein-1 (AP-1) (-207/-201) sites in the 9-kb

103 ear factor of activated T cells (NFATs), and activator protein-1 (AP-1) activation and preceded by a

104 ies Sulfiredoxin (Srx) as a unique target of activator protein-1 (AP-1) activation and TAM67 inhibiti

105 , SAG inhibited TPA-induced c-Jun levels and activator protein-1 (AP-1) activity in both in vitro pri

106 ffect in inducing ERK1/2 phosphorylation and activator protein-1 (AP-1) activity in both primary Syri

107 enzo(a)pyrene diol-epoxide [B(a)PDE]-induced activator protein-1 (AP-1) activity in mouse epidermal C

108 ated with an increase in VEGF transcription, activator protein-1 (AP-1) activity, and JunB accumulati

109 GSK3beta activation significantly stimulated activator protein-1 (AP-1) activity.

110 Six of these factors, including activator protein-1 (AP-1) and cAMP responsive element b

111 rapy-induced HB-EGF was largely dependent on activator protein-1 (AP-1) and NF-kappaB activation.

112 factor of activated T-cells (NFAT), but not activator protein-1 (AP-1) and NFkappaB, suggesting that

113 Fos and Jun are components of activator protein-1 (AP-1) and play crucial roles in the

114 Previously, we implicated Akt and activator protein-1 (AP-1) as mediators of growth and ge

115 ent on nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1) binding and sensitive to phar

116 region of CXCL16 and identified a functional activator protein-1 (AP-1) binding motif.

117 nsive changes following cryoinjury, and that activator protein-1 (AP-1) binding sites are the most hi

118 wo DHSs at -13 kb and -11.5 kb which contain activator protein-1 (AP-1) binding sites, both of which

119 n addition, we found that MTA1/polymerase II/activator protein-1 (AP-1) co-activator complex interact

120 hown that COBRA1 can negatively regulate the activator protein-1 (AP-1) complex at the TFF1 promoter

121 ntify a transcriptional program regulated by activator protein-1 (AP-1) complex, formed by c-Fos and

122 c-Jun is a component of the activator protein-1 (AP-1) complex, which plays a crucia

123 vels of nuclear factor kappaB (NFkappaB) and activator protein-1 (AP-1) DNA binding were increased by

124 -/-)/Apc(Min/+) showed dramatic increases in activator protein-1 (AP-1) DNA binding, and SOCS2 overex

125 Here we show the activator protein-1 (AP-1) factor JunB is an essential r

126 LIP(L) is transcriptionally regulated by the activator protein-1 (AP-1) family member protein c-Fos.

127 The activator protein-1 (AP-1) family transcription factor,

128 The transcription factor activator protein-1 (AP-1) has been implicated as a driv

129 n about the role of the transcription factor activator protein-1 (AP-1) in ABC DLBCL.

130 ssociated with activation of NF- kappa B and activator protein-1 (AP-1) in HEK293A cells but only wit

131 sensus binding site for transcription factor activator protein-1 (AP-1) is required for promoter acti

132 Our studies continue with the Jun/Fos activator protein-1 (AP-1) leucine zipper complex, as it

133 that inhibition of the transcription factor activator protein-1 (AP-1) may contribute to the chemopr

134 in a dose-dependent manner by activating the activator protein-1 (AP-1) member proteins c-FOS, JunD,

135 The levels of activator protein-1 (AP-1) mRNA and protein, as well as

136 Additionally, JunD but not JunB formed an activator protein-1 (AP-1) oligomeric complex to augment

137 Activator protein-1 (AP-1) regulates a wide range of cel

138 Activator protein-1 (AP-1) regulates diverse gene respon

139 0 and IL-12Rbeta2 via inhibition of the MAPK-activator protein-1 (AP-1) signaling pathway.

140 f transcription factors to the NF-kappaB and activator protein-1 (AP-1) sites on the IL-6 promoter.

141 ven genes by attenuating the availability of activator protein-1 (AP-1) sites to Jun family signal-de

142 omoting redistribution of TAp73 from TP53 to activator protein-1 (AP-1) sites.

143 ctor-beta1 (TGF-beta1) signaling to activate activator protein-1 (AP-1) that in turn transcriptionall

144 to the pro-inflammatory transcription factor activator protein-1 (AP-1) through protein-protein inter

145 proteins NFAT1-4 and NF-kappaB complex with activator protein-1 (AP-1) to transactivate target genes

146 to the c-fos promoter resulting in increased activator protein-1 (AP-1) transactivation.

147 gh EGF receptor and Akt results in increased activator protein-1 (AP-1) transcription factor activity

148 The proto-oncogene c-Jun is a component of activator protein-1 (AP-1) transcription factor complexe

149 Because of the important role of the activator protein-1 (AP-1) transcription factor in cance

150 nic, linkage and microarray studies that the activator protein-1 (AP-1) transcription factor JunD is

151 ilitates latent infection by attenuating the activator protein-1 (AP-1) transcription factor subunit,

152 is an IDP that acts as a potentiator of the Activator Protein-1 (AP-1) transcription factor.

153 ty, which was associated with recruitment of activator protein-1 (AP-1) transcription factors and was

154 To examine the consequences of inhibiting activator protein-1 (AP-1) transcription factors in skin

155 o the nuclear factor kappa B (NF-kappaB) and activator protein-1 (AP-1) transcriptional activators.

156 ated TF expression depended most strongly on activator protein-1 (AP-1) transcriptional activity and

157 sphorylation and a corresponding increase in activator protein-1 (AP-1) transcriptional activity.

158 ranscriptional activation of c-Fos-dependent activator protein-1 (AP-1) via serum response factor (SR

159 e sulfate activates the transcription factor activator protein-1 (AP-1) via stimulation of transient

160 haracteristically contained motifs that bind activator protein-1 (AP-1), a pivotal regulator of infla

161 TNF is a potent inducer of activator protein-1 (AP-1), and flavopiridol abrogated t

162 -1), Sp1, nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and hypoxia-inducible factor

163 , such as nuclear factor kappaB (NF-kappaB), activator protein-1 (AP-1), and signal transduction and

164 rm of the immune response in the presence of activator protein-1 (AP-1), and T cell anergy/exhaustion

165 The transcription factor, activator protein-1 (AP-1), binds to cognate DNA under r

166 cer of activated B cells (NF-kappaB), STAT3, activator protein-1 (AP-1), hypoxia-inducible factor-1 (

167 e-induced promoter activity of NF-kappaB and activator protein-1 (AP-1), indicating that NF-kappaB an

168 which is a component of transcription factor activator protein-1 (AP-1), to the promoter region of mi

169 elevated CYR61 induced transcription factor activator protein-1 (AP-1), which functions to stimulate

170 Pdcd4 inhibited by 46% TPA-induced activator protein-1 (AP-1)-dependent transcription, an e

171 ranscription factor-2 or JunD, and increased activator protein-1 (AP-1)-mediated endogenous transcrip

172 e wg expression through transcription factor activator protein-1 (AP-1).

173 e transcription factors NF-kappaB itself and activator protein-1 (AP-1).

174 ctors nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1).

175 C2/Rbx2 is a novel transcriptional target of activator protein-1 (AP-1).

176 S-2 and IGF-I, requires transcription factor activator protein-1 (AP-1).

177 oblast differentiation via the activation of activator protein-1 (AP-1).

178 receptor 1) was identified as a novel c-Fos/activator protein-1(AP-1)-regulated gene.

179 es which also contain many binding sites for activator protein 1 (AP1) and cyclic AMP response elemen

180 ensus DNA sequence for transcription factors activator protein 1 (AP1) and specificity protein 1 (SP1

181 tion factor (GABP-alpha) to their respective activator protein 1 (AP1) and v-ets erythroblastosis vir

182 high-throughput sequencing, we identify the activator protein 1 (AP1) as a major partner for product

183 increased in SUM44/LCCTam, and inhibition of activator protein 1 (AP1) can restore or enhance TAM sen

184 ase kinase 7 (MKK7)/c-Jun-NH(2)-kinase (JNK)/activator protein 1 (AP1) cascade.

185 Deregulation of the activator protein 1 (AP1) family gene regulators has bee

186 The activator protein 1 (AP1) family transcription factor BA

187 its relationship to the transcription factor activator protein 1 (AP1) in CHF rabbits and in the CATH

188 extracellular signal-regulated kinase (Erk)-activator protein 1 (Ap1) pathway seems to mediate the e

189 obility supershift assay using an involucrin activator protein 1 (AP1) response element sequence reve

190 including nuclear factor-kappaB (NF-kappaB), activator protein 1 (AP1), signal transducer and activat

191 ein (CHOP), X2-Box-binding protein 1 (XBP1), activator protein 1 (AP1), SMAD, CCAAT/enhancer-binding

192 we identified several functional NF-kappaB, activator protein 1 (AP1), STAT, and Smad DBS in the TSL

193 on in nonsteroidogenic cells, likely through activator protein 1 (AP1).

194 affect the ubiquitin-editing enzyme A20 and activator protein 1 (AP1).

195 sion that is mediated by DNA-bound NF-kappaB/activator protein 1 (AP1)/STAT3 activators and instrumen

196 tion factors such as nuclear factor B (NFB), activator protein-1 (AP1) and heat shock factor 1 (HSF1)

197 ressed, IRF4 unexpectedly can cooperate with activator protein-1 (AP1) complexes to bind to AP1-IRF4

198 ERK activity promoted the expression of the activator protein-1 (AP1) components Fra-1 and c-Jun, bo

199 such as nuclear factor-kappaB (NFkappaB) and activator protein-1 (AP1) for 24 hours after separation

200 The activator protein-1 (AP1) transcription complex remains

201 ear factor of activated T cells c1 (NFATc1), activator protein-1 (AP1), and NF-kappaB.

202 3beta (hepatocyte nuclear factor 3) and AP-1(activator protein 1) as proteins likely to be involved i

203 late Mmp13 expression via the P2rx7/MAPK/ERK/activator protein 1 axis.

204 atin immunoprecipitation (ChIP), we detected activator protein-1 binding within an evolutionarily con

205 essibility were highly associated with AP-1 (activator protein 1) binding sites.

206 by COOH-truncated HBx was abolished when the activator protein 1-binding sites on the MMP10 promoter

207 on of the inflammatory transcription factor, activator protein 1, but not NF-kappaB was observed.

208 otein-1 reporter activity, but activation of activator protein-1 by the three SLK mutants was ineffec

209 HGF treatment caused activation of the activator protein-1, CCAAT/enhancer-binding protein, and

210 possibly because of decreased activation of activator protein-1, compared with control cells overexp

211 ing of a phosphorylated c-Jun containing the activator protein 1 complex to the PUMA promoter was ide

212 FRA-1 forms activator protein-1 complexes in association with member

213 X1, PREP1 induces the expression of multiple activator protein 1 components including the proinvasive

214 th the inflammatory cytokines and/or various activator protein-1 constructs.

215 ncreased SRF phosphorylation activates AP-1 (activator protein-1)-dependent enhancers that direct myo

216 r ubiquitination and degradation, disrupting activator protein 1-dependent TGF-beta autoinduction.

217 ions involving several signaling modulators, activator protein-1-dependent gene expression remains hi

218 was not due to an increase in NF-kappaB- or activator protein-1-dependent IL-8 promoter transcriptio

219 the nuclear factor of activated T cell- and activator protein-1-dependent signaling pathways, which

220 y phosphorylation of c-Jun and activation of activator protein-1-dependent transcription.

221 RK2), in turn leading to inhibition of c-Jun/activator protein-1-dependent transcriptional activity.

222 oblast mmp9 and mmp13 promoters, established activator protein 1 effectors.

223 kappaB) and epidermal growth factor receptor-activator protein-1 (EGFR-AP1) pathways are often co-act

224 transcription through the recruitment of an activator protein-1/estrogen receptor-alpha (ER alpha) c

225 ivated involucrin promoter activity, nuclear activator protein-1 factor accumulation and binding to D

226 ene c-jun encodes the founding member of the activator protein-1 family and is required for cellular

227 oto-oncogene subunit), a member of the AP-1 (activator protein-1) family of transcription factors, is

228 ization of their regulators (Rap1 [repressor activator protein 1], Fhl1, Ifh1, Sfp1, and Hmo1), the t

229 LPS transcriptionally activates YAP through activator protein 1 in macrophages/KCs.

230 ncreases the expression of ET(A) R, OBRb and activator protein-1 in HSCs.

231 ion of mitogen-activated protein kinases and activator protein-1 in myofibers of mdx mice.

232 anscriptional activity of both NF-kappaB and activator protein 1, in part by means of recruitment of

233 AR-small interfering RNA or treated with the activator protein-1 inhibitor SR-11302 [3-methyl-7-(4-me

234 Activator protein 1 is known as a pivotal regulator of m

235 Rap1 (repressor activator protein 1) is a conserved multifunctional prot

236 Rap1 (repressor-activator protein 1) is a multifunctional protein that c

237 of GATA2 (GATA-binding protein 2) and AP-1 (activator protein 1) is significantly lower compared wit

238 ing from GPCRs and RhoA to the regulation of activator protein-1, NFkappaB (nuclear factor kappa-ligh

239 xtracellular signal-regulated kinase 1/2 and activator protein-1 nuclear factors in IL-13Ralpha2-posi

240 matory transcription control pathways (i.e., activator protein-1, nuclear factor-kappaB) in response

241 NA-binding activity of transcription factors activator protein-1, nuclear factor-kappaB, and Stat3; a

242 ygenase-2 expression, the transactivation of activator protein-1 or nuclear factor-kappaB, or MEK.

243 No significant alterations were observed for activator protein 1, p53 or Akt activity.

244 These results demonstrate that the c-Jun/activator protein 1 pathway is critical for maintaining

245 tivated the mitogen-activated protein kinase/activator protein 1 pathway, together with the inflammas

246 y signaling in addition to the classic c-Jun/activator protein 1 pathway, which provided the first ev

247 its target gene programmed cell death 4 and activator protein 1 pathway.

248 llular injury response through PDCD4 and the activator protein 1 pathway.

249 kinase 1/2 mitogen-activated protein kinase/activator protein-1 pathway activation.

250 s Hoxc6 with oncogenic signaling through the activator protein-1 pathway in carcinoid tumorigenesis.

251 ceptor gamma agonist rosiglitazone decreased activator protein 1 promoter activity.

252 Repressor activator protein 1 (RAP1) and telomeric repeat-binding

253 sphatase (PIP5Pase) interacts with repressor activator protein 1 (RAP1) in a multiprotein complex and

254 Repressor/activator protein 1 (RAP1) is a highly conserved telomer

255 Repressor activator protein 1 (Rap1) performs multiple vital cellu

256 We show that repressor-activator protein 1 (Rap1), a master regulator of yeast

257 ide direct evidence that the yeast repressor/activator protein 1 (Rap1), tightly bound to its consens

258 ct contact with the transactivator repressor activator protein 1 (Rap1).

259 rolled by the transcription factor repressor activator protein 1 (Rap1p) in a TFIID-dependent fashion

260 ssive activation of the transcription factor activator protein 1, reduced histone deacetylase-2 (HDAC

261 the telomere-binding protein Rap1 (repressor activator protein 1) relocalizes to the upstream promote

262 Similarly, SLK WT stimulated activator protein-1 reporter activity, but activation of

263 ERbeta-dependent retardation of migration of activator protein-1 response elements in EMSA.

264 Our findings demonstrate that the JNK/activator protein 1 signaling pathway underlies the mela

265 ated by cyclooxygenase/nuclear factor-kappaB/activator protein 1 signaling pathways.

266 xpression is up-regulated by ROS through the activator protein-1 signaling pathway and promotes cell

267 Hoxc6 activated the oncogenic activator protein-1 signaling pathway through a physical

268 dermal cells by targeting the MEK/ERK/p90RSK/activator protein-1 signaling pathway.

269 l-regulated kinase 1/2 pathway, involving an activator protein 1 site in MMP10 gene promoter.

270 the region of the PR gene containing the +90 activator protein 1 site, but not with the ERE-containin

271 d transcriptional activation of the relevant activator protein-1 site in the human TGFbeta1 promoter.

272 enhanced c-Fos/c-Jun binding to the proximal activator protein-1 site of the StAR promoter in HPAECs,

273 binding of c-Fos and c-Jun to Mmp-9 promoter activator protein 1 sites.

274 rotein partner of DeltaFosB binding to AP-1 (activator protein-1) sites of genes, remained unchanged

275 Batf belongs to the activator protein 1 superfamily of basic leucine zipper

276 TbPIP5Pase associates with repressor/activator protein 1 (TbRAP1), and their telomeric silenc

277 Tax is shown to activate activator protein-1 through the phosphatidylinositol 3-k

278 absence of NF-kappaB signaling, can activate activator protein-1 to promote cellular proliferation an

279 and E7 were mediated by enhanced binding of activator protein-1 to the cyclic AMP (cAMP)-responsive

280 Ser(63) and Ser(73), resulting in increased activator protein-1 transactivation.

281 a highly conserved member of the multimeric activator protein 1 transcription factor complex and pla

282 suprabasal epidermis-specific inhibition of activator protein 1 transcription factor signaling.

283 stically, the LMO7 LIM domain interacts with activator protein 1 transcription factor subunits c-FOS

284 kappaB p65, and the nuclear translocation of activator protein 1 transcription factor.

285 -13 promoters that contain binding sites for activator protein 1 transcription factors.

286 ough serine 84 phosphorylation and promoting activator protein 1 transcription.

287 on, emphasizing compositional differences in activator protein-1 transcription factor activity and ex

288 The oncoprotein c-Jun is a component of the activator protein-1 transcription factor complex, which

289 V-1 and HTLV-2 but instead contains a unique activator protein-1 transcription factor upstream of the

290 y our study indicated that MAPK pathways and activator protein-1 transcription factor were involved i

291 ell as their major downstream effectors--the activator protein-1 transcription factors c-Fos and c-Ju

292 with increased expression of Fra-1 and JunD, activator protein-1 transcription factors known to be re

293 IL-1beta signaling converges upon the activator protein-1 transcription factors, which have be

294 ng protein kinase Calpha and is dependent on activator protein-1 transcription factors.

295 tion and nuclear factor of activated T cells/activator protein 1 transcriptional activity.

296 Although the c-Jun/activator protein 1 transcriptional factor regulates cel

297 by Cav1 knockdown to increased expression of activator protein-1 transcriptional targets, including c

298 tor, endothelin-1 type A receptor (ET(A) R), activator protein-1, transforming growth factor beta (TG

299 Moreover, activator protein 1 was a downstream signaling molecule

300 Soluble LT also led to the activation of activator protein 1, whereas LT(+) vesicle IL-6 response